

Pierre-Olivier Fernagut

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6098353/pierre-olivier-fernagut-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

4,834
citations

35
h-index

69
g-index

91
ext. papers

5,521
ext. citations

6.2
avg, IF

5.26
L-index

#	Paper	IF	Citations
83	Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021 , 7, 112	9.7	1
82	Sleep deprivation reduces vagal tone during an inspiratory endurance task in humans. <i>Sleep</i> , 2021 , 44,	1.1	1
81	Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. <i>Biomedicines</i> , 2021 , 9,	4.8	3
80	L-DOPA regulates β synuclein accumulation in experimental parkinsonism. <i>Neuropathology and Applied Neurobiology</i> , 2021 , 47, 532-543	5.2	5
79	Mass spectrometry imaging identifies abnormally elevated brain L-DOPA levels and extrastriatal monoaminergic dysregulation in L-DOPA-induced dyskinesia. <i>Science Advances</i> , 2021 , 7,	14.3	6
78	Comparison of the expression and toxicity of AAV2/9 carrying the human A53T β synuclein gene in presence or absence of WPRE. <i>Heliyon</i> , 2021 , 7, e06302	3.6	1
77	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020 , 143, 1780-1797	11.2	21
76	Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. <i>Movement Disorders</i> , 2020 , 35, 1163-1172	7	4
75	l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model. <i>Movement Disorders</i> , 2019 , 34, 1237	7	
74	Sex-dependent behavioral deficits and neuropathology in a maternal immune activation model of autism. <i>Translational Psychiatry</i> , 2019 , 9, 124	8.6	39
73	Multiple System Atrophy: Recent Developments and Future Perspectives. <i>Movement Disorders</i> , 2019 , 34, 1629-1642	7	28
72	Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. <i>JCI Insight</i> , 2019 , 4,	9.9	30
71	Dopamine and addiction: what have we learned from 40 years of research. <i>Journal of Neural Transmission</i> , 2019 , 126, 481-516	4.3	40
70	Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019 , 75, 126-135	5.6	11
69	Impulse control disorders in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018 , 125, 1299-1312	4.3	17
68	Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy. <i>Neurobiology of Disease</i> , 2018 , 118, 155-160	7.5	3
67	Motor Impairments Correlate with Social Deficits and Restricted Neuronal Loss in an Environmental Model of Autism. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 871-882	5.8	19

66	Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. <i>Lancet Neurology</i> , 2017 , 16, 238-250	24.1	207
65	Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. <i>Human Molecular Genetics</i> , 2017 , 26, 2603-2615	5.6	26
64	Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. <i>Movement Disorders</i> , 2017 , 32, 1230-1239	7	31
63	Multiple System Atrophy - State of the Art. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 41	6.6	21
62	Insulin resistance and exendin-4 treatment for multiple system atrophy. <i>Brain</i> , 2017 , 140, 1420-1436	11.2	50
61	Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. <i>Scientific Reports</i> , 2017 , 7, 2348	4.9	5
60	Selective Inactivation of Striatal FosB/ΔosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2016 , 79, 354-361	7.9	58
59	Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 9593-8	11.5	67
58	Targeting βsynuclein: Therapeutic options. <i>Movement Disorders</i> , 2016 , 31, 882-8	7	33
57	Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2016 , 79, 345-353	7.9	12
56	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. <i>Neurobiology of Disease</i> , 2016 , 89, 55-64	7.5	20
55	Multi-faceted impulsivity following nigral degeneration and dopamine replacement therapy. <i>Neuropharmacology</i> , 2016 , 109, 69-77	5.5	20
54	Alpha-synuclein-based models of Parkinson's disease. <i>Revue Neurologique</i> , 2016 , 172, 371-8	3	31
53	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 6-16	2.2	15
52	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015 , 132, 96-168	10.9	282
51	Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by βsynuclein overexpression. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 46	7.3	65
50	Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. <i>Cerebral Cortex</i> , 2015 , 25, 2783-92	5.1	38
49	Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy. <i>Movement Disorders</i> , 2015 , 30, 1802-12	7	7

48	Premotor parkinsonism models. <i>Parkinsonism and Related Disorders</i> , 2014 , 20 Suppl 1, S17-9	3.6	15
47	Lewy body extracts from Parkinson disease brains trigger β -synuclein pathology and neurodegeneration in mice and monkeys. <i>Annals of Neurology</i> , 2014 , 75, 351-62	9.4	427
46	Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. <i>Neurobiology of Disease</i> , 2014 , 67, 133-9	7.5	25
45	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. <i>Progress in Neurobiology</i> , 2014 , 118, 1-18	10.9	143
44	Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. <i>Neurobiology of Disease</i> , 2014 , 62, 179-92	7.5	54
43	Dopamine control of pyramidal neuron activity in the primary motor cortex via D2 receptors. <i>Frontiers in Neural Circuits</i> , 2014 , 8, 13	3.5	28
42	Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. <i>Synapse</i> , 2014 , 68, 98-106	2.4	29
41	Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. <i>Movement Disorders</i> , 2014 , 29, 388-95	7	25
40	Reinforcing properties of Pramipexole in normal and parkinsonian rats. <i>Neurobiology of Disease</i> , 2013 , 49, 79-86	7.5	26
39	Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. <i>Annals of Neurology</i> , 2013 , 74, 140-4	9.4	38
38	Animal models of multiple system atrophy. <i>Neuroscience</i> , 2012 , 211, 77-82	3.9	31
37	Ambiguous mechanisms of dysphagia in multiple system atrophy. <i>Brain</i> , 2012 , 135, e205; author reply e206	11.2	7
36	Links between glucocerebrosidase and alpha-synuclein revealed. <i>Movement Disorders</i> , 2011 , 26, 2177	7	0
35	NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid. <i>Neurological Research</i> , 2011 , 33, 444-7	2.7	1
34	Protein aggregation in the aging retina. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011 , 70, 63-8	3.1	61
33	Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism. <i>Neurological Research</i> , 2010 , 32, 1050-3	2.7	2
32	Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. <i>PLoS ONE</i> , 2010 , 5, e14053	3.7	46
31	The nigrostriatal pathway in Creutzfeldt-Jakob disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009 , 68, 809-15	3.1	21

30	Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. <i>Neurobiology of Disease</i> , 2009 , 33, 182-92	7.5	27
29	Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. <i>Lancet Neurology</i> , 2009 , 8, 1140-9	24.1	289
28	Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. <i>Neurobiology of Disease</i> , 2009 , 35, 477-88	7.5	50
27	Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. <i>Journal of Biological Chemistry</i> , 2008 , 283, 34696-703	5.4	64
26	Environmental Explorations of Parkinson's Disease Using Rodent Genetic Models 2008 , 285-294		1
25	Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. <i>Synapse</i> , 2007 , 61, 991-1001	2.4	149
24	Direct regulation of adult brain function by the male-specific factor SRY. <i>Current Biology</i> , 2006 , 16, 415-20	20.3	268
23	Genetic mouse models of parkinsonism: strengths and limitations. <i>NeuroRx</i> , 2005 , 2, 495-503		131
22	Parkinson's disease models: From toxins to genes. <i>Drug Discovery Today: Disease Models</i> , 2005 , 2, 299-303	3.3	3
21	In vivo models of multiple system atrophy. <i>Movement Disorders</i> , 2005 , 20 Suppl 12, S57-63	7	10
20	Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. <i>Journal of Neural Transmission</i> , 2005 , 112, 613-31	4.3	26
19	Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons. <i>Journal of Neurophysiology</i> , 2005 , 94, 3662-9	3.2	56
18	Early Behavioral Phenotypes in Mouse Models of Huntington's and Parkinson's Diseases 2005 , 349-359		
17	Double-Lesion Animal Models of Multiple System Atrophy 2005 , 571-583		
16	Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. <i>European Journal of Neuroscience</i> , 2004 , 19, 3266-76	3.5	141
15	Variable effects of chronic subcutaneous administration of rotenone on striatal histology. <i>Journal of Comparative Neurology</i> , 2004 , 478, 418-26	3.4	77
14	Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. <i>Journal of Neuroscience</i> , 2004 , 24, 9434-40	6.6	369
13	MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. <i>Experimental Neurology</i> , 2004 , 185, 47-62	5.7	48

12	Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. <i>Experimental Neurology</i> , 2004 , 187, 418-29	5.7	151
11	Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. <i>Neurobiology of Disease</i> , 2004 , 15, 667-75	7.5	17
10	Alpha-synuclein and transgenic mouse models. <i>Neurobiology of Disease</i> , 2004 , 17, 123-30	7.5	163
9	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). <i>Acta Neuropathologica</i> , 2003 , 106, 157-66	14.3	46
8	Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. <i>Neuroscience</i> , 2003 , 116, 1123-30	3.9	70
7	Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. <i>European Journal of Neuroscience</i> , 2002 , 15, 2053-6	3.5	28
6	A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. <i>Journal of Neuroscience Methods</i> , 2002 , 113, 123-30	3	156
5	Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. <i>Neuroscience Letters</i> , 2002 , 335, 34-8	3.3	29
4	Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. <i>Neuroscience</i> , 2002 , 114, 1005-17	3.9	129
3	A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. <i>Neuroscience</i> , 2002 , 115, 533-46 ^{3,9}	3.9	54
2	Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. <i>Experimental Neurology</i> , 2001 , 167, 133-47	5.7	47
1	Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. <i>Movement Disorders</i> , 2000 , 15, 531-6	7	36